,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1195,1,2,,48416268,4171,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
1,1332,1,1,,49698871,4171,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
2,2059,1,2,,85209393,4171,Active,,,,,Ligands of Class C GPCRs,Other,,
3,2061,1,2,,85209393,4171,Active,,,,,Ligands of nucleotide-like (Class A) GPCRs,Other,,
4,2062,1,2,,85209393,4171,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
5,2063,1,2,,85209393,4171,Active,,,,,Ligands of peptide (Class A) GPCRs,Other,,
6,2064,1,2,,85209393,4171,Active,,,,,Ligands of prostanoid (Class A) GPCRs,Other,,
7,2240,1,1,,85789202,4171,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
8,2241,1,1,,85789202,4171,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
9,2275,1,1,,85789202,4171,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
10,2313,1,1,,85789202,4171,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
11,2322,1,1,,85789202,4171,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
12,2330,1,1,,85789202,4171,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
13,4411,5,1,,103164420,4171,Active,,,10.0,Ki,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,Confirmatory,8568799.0,
14,7779,3,3,,103164420,4171,Unspecified,,,,,Oral bioavailability in human,Other,11784135.0,
15,7783,3,4,,103164420,4171,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
16,7812,3,3,,103164420,4171,Unspecified,,,,,In vitro rate of absorption observed as Caco-2 permeability in humans,Other,11784135.0,
17,7974,3,4,,103164420,4171,Unspecified,,,,,Metabolic stability observed at 30 min after administration in human liver microsomes,Other,11784135.0,
18,8002,5,2,,103164420,4171,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
19,15120,3,3,,103164420,4171,Unspecified,,,,,Percent of the drug absorbed after administration to humans was determined,Other,10346926.0,
20,18847,3,4,,103164420,4171,Unspecified,,,,,Percent of drug absorbed by human intestine after oral administration,Other,11020286.0,
21,18849,3,4,,103164420,4171,Unspecified,,,,,Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.,Other,10841786.0,
22,19006,4,3,,103164420,4171,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
23,19419,3,4,,103164420,4171,Unspecified,,,,,Partition coefficient (logD7.4),Other,9544199.0,
24,19424,3,4,,103164420,4171,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
25,20050,3,3,,103164420,4171,Unspecified,,,,,Human absorption A (%),Other,9544199.0,
26,21254,3,4,,103164420,4171,Unspecified,,,,,Mono layer permeability of human intestinal Caco-2 cells,Other,9876108.0,
27,22293,4,4,,103164420,4171,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
28,23672,3,3,,103164420,4171,Unspecified,,,,,Partition coefficient (logP),Other,7381857.0,
29,25572,3,4,,103164420,4171,Unspecified,,,,,Dissociation constant of the compound,Other,9876108.0,
30,25870,3,3,,103164420,4171,Unspecified,,,,,Tested for the dissociation constant of the compound,Other,7381857.0,
31,26304,4,4,,103164420,4171,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
32,26362,4,3,,103164420,4171,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
33,26525,3,4,,103164420,4171,Unspecified,,,,,Distribution coefficient measured in Octanol/buffer (0.15 M KCl),Other,9876108.0,
34,27549,3,4,,103164420,4171,Unspecified,,,,,Lipophilicity for the compound was determined,Other,2884312.0,
35,28233,3,3,,103164420,4171,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
36,28234,3,4,,103164420,4171,Unspecified,,,,,% absorbed in human GI-tract,Other,11300874.0,
37,28235,3,3,,103164420,4171,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
38,28236,3,3,,103164420,4171,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
39,28392,3,3,,103164420,4171,Unspecified,,,,,Apparent permeability coefficient (Papp) (Caco-2 cell monolayer),Other,11384238.0,
40,28399,3,3,,103164420,4171,Unspecified,,,,,Cellular permeability (Pc) (Caco-2 cell monolayer),Other,11384238.0,
41,28679,3,4,,103164420,4171,Unspecified,,,,,Partition coefficient (logD6.8),Other,11300874.0,
42,28921,3,3,,103164420,4171,Unspecified,,,,,Partition coefficient (logP) (hexadecane),Other,11300874.0,
43,28924,3,3,,103164420,4171,Unspecified,,,,,Effective permeability (Pe) across a hexadecane membrane (pH 6.8),Other,11300874.0,
44,28925,3,3,,103164420,4171,Unspecified,,,,,Highest effective permeability across hexadecane membrane (pH 4-8),Other,11300874.0,
45,28926,3,3,,103164420,4171,Unspecified,,,,,Effective permeability corrected for ionization,Other,11300874.0,
46,28928,3,3,,103164420,4171,Unspecified,,,,,Intrinsic permeability of the compound,Other,11300874.0,
47,29139,4,3,,103164420,4171,Unspecified,,,,,"Calculated dissociation constant (pKa, calculated with ACD/pKa)",Other,12477351.0,
48,29337,3,3,,103164420,4171,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
49,29359,3,3,,103164420,4171,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
50,29423,3,4,,103164420,4171,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
51,29811,4,3,,103164420,4171,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
52,29844,3,3,,103164420,4171,Unspecified,,,,,Fraction absorbed after oral administration in humans,Other,11384238.0,
53,29925,5,2,,103164420,4171,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
54,39943,9,2,,103164420,4171,Active,,,0.014790000000000001,Kd,In vitro inhibitory activity against beta-1 adrenergic receptor measured by inhibition of positive chronotropic effect of isoproterenolin in isolated guinea pig atria,Confirmatory,2872332.0,
55,40420,6,3,,103164420,4171,Active,,,0.02291,Kd,Antagonist activity was determined against beta-1 adrenergic receptor in spontaneously beating rat atria,Confirmatory,2884312.0,
56,40527,5,3,,103164420,4171,Active,,,0.02291,Kd,Cardioselectivity for the beta-1 adrenergic receptor was determined against isoprenaline (antagonism) in isolated rat atria,Confirmatory,2884312.0,
57,40537,3,7,,103164420,4171,Active,,,,,Selectivity for beta-1 adrenergic receptor,Other,2903243.0,
58,40868,7,6,,103164420,4171,Active,81914759.0,100722663.0,0.16218,Kd,Beta-2 adrenergic receptor antagonistic activity on guinea pig tracheal chains,Confirmatory,6126588.0,
59,40869,9,5,,103164420,4171,Active,81914759.0,100722663.0,0.16218,Kd,In vitro beta-2 adrenergic receptor activity was determined by measuring inhibition of the isoproterenol induced relaxation in isolated guinea pig tracheal chains contracted with PGF2-alpha,Confirmatory,6134834.0,
60,40870,9,5,,103164420,4171,Active,81914759.0,100722663.0,0.16218,Kd,In vitro inhibitory activity against beta-2 adrenergic receptor was measured by the inhibition of isoproterenol-induced relaxation of PGF2-alpha contracted guinea pig trachea,Confirmatory,2872332.0,
61,41350,7,3,,103164420,4171,Unspecified,,,,,Beta-2 adrenergic receptor antagonist activity as the dose required to inhibit 50% of vasopressor response in anesthetized rats,Other,6138435.0,
62,41487,3,7,,103164420,4171,Inactive,,,,,Selectivity towards beta-2 adrenergic receptor; Nonselective towards beta-2 adrenergic receptor,Other,2903243.0,
63,41890,3,6,,103164420,4171,Active,,,,,Tested for intrinsic sympathomimetic activity (ISA); Pure antagonist,Other,2903243.0,
64,41895,3,7,,103164420,4171,Unspecified,,,,,Beta-blocking activity was measured by applying the stepwise linear discriminate analysis; Active,Other,,
65,42210,6,2,,103164420,4171,Active,,,0.72444,Kd,Cardioselectivity for the beta-1 adrenergic receptor was determined against isoprenaline (antagonism) in isolated guinea pig trachea,Confirmatory,2884312.0,
66,42214,7,2,,103164420,4171,Active,,,0.014790000000000001,Kd,Compound was tested for its Beta-1 adrenergic receptor antagonistic activity on guinea pig arteria,Confirmatory,6126588.0,
67,42218,9,3,,103164420,4171,Active,,,0.014790000000000001,Kd,In vitro beta-1 adrenergic receptor activity was determined via inhibition of the positive chronotropic actions of isoproterenol in isolated guinea pig atrial preparations,Confirmatory,6134834.0,
68,45282,7,1,,103164420,4171,Unspecified,,,,,Absorptive transport in Caco-2 cells in comparison to metoprolol,Other,10753475.0,
69,45284,3,4,,103164420,4171,Unspecified,,,,,Efflux in Caco-2 cells; no,Other,10753475.0,
70,45286,7,1,,103164420,4171,Unspecified,,,,,Secretory Transport in Caco-2 cells in comparison to metoprolol,Other,10753475.0,
71,45287,4,1,,103164420,4171,Unspecified,,,,,permeability in Caco-2 cells; no,Other,10753475.0,
72,71778,3,3,,103164420,4171,Unspecified,,,,,Local anesthetic activity against beta-1 adrenoceptor was determined with reference to activity(1) of propranolol (beta blocker),Other,2884312.0,
73,78477,3,4,,103164420,4171,Unspecified,,,,,Ability to bind to guinea pig atrial homogenate,Other,7381857.0,
74,91480,3,8,,103164420,4171,Unspecified,,,,,Ability to bind to human serum albumin (HSA),Other,7381857.0,
75,91481,4,7,,103164420,4171,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
76,150618,9,2,,103164420,4171,Unspecified,,,1300.0,IC50,Concentration required for 50% inhibition at binding site of human P-Glycoprotein (P-gp) in one-affinity model,Confirmatory,12477351.0,
77,150735,9,2,,103164420,4171,Unspecified,,,200.0,Ki,High affinity constant at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Confirmatory,12477351.0,
78,150736,3,8,,103164420,4171,Unspecified,,,,,Fraction of high affinity at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Other,12477351.0,
79,156089,3,4,,103164420,4171,Unspecified,,,,,Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system,Other,10841786.0,
80,156203,3,4,,103164420,4171,Unspecified,,,,,Binding to POPC/GMI liposomes using biosensor system,Other,10841786.0,
81,168349,4,4,,103164420,4171,Unspecified,,,,,Stereoselectivity in presence of rat liver microsomes,Other,3336032.0,
82,177028,3,7,,103164420,4171,Unspecified,,,,,Beta agonist activity against heart rate in rats,Other,6142955.0,
83,177029,4,8,,103164420,4171,Unspecified,,,,,Beta agonistic activity as the dose required to increase heart rate by 30 beats/min in anesthetized rats upon intravenous administration,Other,6138435.0,
84,178334,6,3,,103164420,4171,Unspecified,,,,,Inhibition of isoprenaline induced vasopressor response in anaesthetised rats.,Other,6142955.0,
85,178335,6,3,,103164420,4171,Unspecified,,,,,Inhibition of isoprenaline induced tachycardia in anaesthetised rats.,Other,6142955.0,
86,178339,7,3,,103164420,4171,Unspecified,,,,,Beta-1 adrenoceptor blocking activity as the dose required to inhibit 50% of tachycardia in anesthetized rats,Other,6138435.0,
87,190410,4,4,,103164420,4171,Unspecified,,,,,Antihypertensive activity expressed as percentage of base-line systolic blood pressure of base-line values in spontaneously hypertensive rats (SHR) was reported after 24 hr,Other,2884312.0,
88,190411,4,4,,103164420,4171,Unspecified,,,,,Antihypertensive activity expressed as percentage of base-line systolic blood pressure of base-line values in spontaneously hypertensive rats (SHR) was reported after 2 hr,Other,2884312.0,
89,190412,4,4,,103164420,4171,Unspecified,,,,,Antihypertensive activity expressed as percentage of base-line systolic blood pressure of base-line values in spontaneously hypertensive rats (SHR) was reported after 4 hr,Other,2884312.0,
90,205267,9,2,,103164420,4171,Unspecified,,,117.0,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
91,205268,4,7,,103164420,4171,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
92,205269,3,7,,103164420,4171,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM,Other,2579237.0,
93,211857,6,3,,103164420,4171,Unspecified,,,,,Compound was tested for its toxicity after intravenous administration to mice in experiment 1,Other,,
94,211859,6,3,,103164420,4171,Unspecified,,,,,Compound was tested for its toxicity after intravenous administration to mice in experiment 2,Other,,
95,211863,6,3,,103164420,4171,Unspecified,,,,,Compound was tested for its toxicity after oral administration to mice in experiment 1,Other,,
96,211865,6,3,,103164420,4171,Unspecified,,,,,Compound was tested for its toxicity after oral administration to mice in experiment 2,Other,,
97,218541,9,2,,103164420,4171,Active,,,0.5,IC50,The compound was tested for its ability to inhibit (-)-[3H]dihydroalprenolol binding to beta-adrenergic receptor sites in rat cortex,Confirmatory,,
98,218832,7,4,,103164420,4171,Active,,,0.19,IC50,Tested for beta-1-adrenergic blocking effect by measuring the ability to inhibit the positive inotropic effect of isoproterenol on the isolated right atrium of guinea pigs,Confirmatory,,
99,218843,7,3,,103164420,4171,Active,,,0.32,IC50,Tested for beta-2-adrenergic blocking effect by measuring the ability to inhibit the relaxing effect of epinephrine on the isolated tracheal muscle of guinea pigs,Confirmatory,,
100,230146,4,6,,103164420,4171,Unspecified,,,,,The cardioselectivity ratio was obtained by taking the antilog (pA2 beta1-pA2 beta2),Other,2872332.0,
101,230147,4,6,,103164420,4171,Unspecified,,,,,The cardioselectivity ratio was obtained by taking the antilog of (pA2(beta-1)-pA2(beta2)),Other,6134834.0,
102,231105,3,4,,103164420,4171,Unspecified,,,,,Ratio of beta-1-adrenergic blocking effect to that of beta 2 -adrenergic blocking effect,Other,,
103,231333,3,3,,103164420,4171,Unspecified,,,,,Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer),Other,11384238.0,
104,232998,3,3,,103164420,4171,Unspecified,,,,,Degree of Selectivity measured as the antilog of pA2 atria-pA2 trachea,Other,2884312.0,
105,236268,3,4,,103164420,4171,Unspecified,,,,,Fraction absorbed in human intestine after oral administration compound was measured,Other,15658873.0,
106,236912,6,1,,103164420,4171,Unspecified,,,,,Permeability Coefficient in 2/4/A1 cell model,Other,15658873.0,
107,236913,6,1,,103164420,4171,Unspecified,,,,,Permeability Coefficient in Caco-2 cell culture model,Other,15658873.0,
108,236914,6,1,,103164420,4171,Unspecified,,,,,Permeability Coefficient in hexadecane membranes model,Other,15658873.0,
109,236916,6,1,,103164420,4171,Unspecified,,,,,Percentage of mass balance in hexadecane membranes model,Other,15658873.0,
110,236917,3,4,,103164420,4171,Unspecified,,,,,Apparent permeability of the compound was determined inCaco-2 (human colon carcinoma) cells; Activity = Papp 10E-6,Other,15689164.0,
111,236918,3,5,,103164420,4171,Unspecified,,,,,Apparent permeability of the compound was determined in MDCK (madin darby canine kidney) strain I; Activity = Papp 10e-6,Other,15689164.0,
112,237585,5,2,,103164420,4171,Unspecified,,,,,Tested for fraction of oral dose absorbed orally in humans,Other,15857133.0,
113,237685,4,3,,103164420,4171,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
114,241889,6,7,,103164420,4171,Active,84028191.0,1565.0,24.0,IC50,Inhibitory activity against recombinant human Cytochrome P450 2D6 (CYP2D6) after incubated for 45 minutes,Confirmatory,15993593.0,
115,266006,5,1,,103164420,4171,Active,114754.0,24925.0,0.39810999999999996,Ki,Antagonist activity at rat wild type beta-1 adrenergic receptor expressed in CHO cells,Confirmatory,16759089.0,
116,266007,5,1,,103164420,4171,Active,114754.0,24925.0,2.51189,Ki,Antagonist activity at rat beta-1 adrenergic receptor Y356F mutant expressed in CHO cells,Confirmatory,16759089.0,
117,266008,5,1,,103164420,4171,Active,114754.0,24925.0,5.01187,Ki,Antagonist activity at rat beta-1 adrenergic receptor Y356A mutant expressed in CHO cells,Confirmatory,16759089.0,
118,266009,5,1,,103164420,4171,Active,114754.0,24925.0,0.6309600000000001,Ki,Antagonist activity at rat beta-1 adrenergic receptor W134A mutant expressed in CHO cells,Confirmatory,16759089.0,
119,266010,5,1,,103164420,4171,Active,114754.0,24925.0,2.51189,Ki,Antagonist activity at rat beta-1 adrenergic receptor S190A mutant expressed in CHO cells,Confirmatory,16759089.0,
120,288184,9,1,,103164420,4171,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
121,288185,7,1,,103164420,4171,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
122,288192,3,4,,103164420,4171,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
123,288193,3,4,,103164420,4171,Unspecified,,,,,"Flux ionization constant, pKa of the membrane permeability coefficient of the compound",Other,17418579.0,
124,288194,3,5,,103164420,4171,Unspecified,,,,,"Intrinsic artificial membrane permeability coefficient, log P0 of the compound",Other,17418579.0,
125,311367,3,6,,103164420,4171,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
126,312895,3,4,,103164420,4171,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18189348.0,
127,312896,3,4,,103164420,4171,Unspecified,,,,,"Partition coefficient, log P by UPLC method",Other,18189348.0,
128,337884,4,4,,103164420,4171,Active,,,0.045,Ki,Displacement of [125I]dihydroalprenolol from beta adrenergic receptor,Confirmatory,8496700.0,
129,338168,3,4,,103164420,4171,Unspecified,,,,,Displacement of [125I]dihydroalprenolol from beta adrenergic receptor assessed as specific binding relative to total binding,Other,8496700.0,
130,350216,3,3,,103164420,4171,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19397318.0,
131,350217,3,3,,103164420,4171,Unspecified,,,,,"Octanol-water partition coefficient, log Pn of the compound",Other,19397318.0,
132,350218,3,4,,103164420,4171,Unspecified,,,,,"Octanol-water partition coefficient, log PC of the compound",Other,19397318.0,
133,350219,3,4,,103164420,4171,Unspecified,,,,,"Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 95% acetonitrile as mobile phase",Other,19397318.0,
134,350220,3,4,,103164420,4171,Unspecified,,,,,"Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 100% water as mobile phase",Other,19397318.0,
135,373867,6,3,,103164420,4171,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
136,386623,4,8,,103164420,4171,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
137,395325,3,3,,103164420,4171,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
138,395328,3,3,,103164420,4171,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
139,404304,3,10,,103164420,4171,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
140,425652,7,2,,103164420,4171,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
141,425653,7,2,,103164420,4171,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
142,434959,1,1,,85789202,4171,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
143,444050,7,1,,103164420,4171,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
144,444051,6,2,,103164420,4171,Unspecified,,,,,Total clearance in human,Other,20070106.0,
145,444052,6,2,,103164420,4171,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
146,444053,6,2,,103164420,4171,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
147,444054,6,1,,103164420,4171,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
148,444055,3,3,,103164420,4171,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
149,444056,3,3,,103164420,4171,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
150,444057,3,3,,103164420,4171,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
151,444058,6,2,,103164420,4171,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
152,453203,3,4,,103164420,4171,Unspecified,,,,,"Lipophilicity, log D of the compound",Other,19963379.0,
153,453204,3,6,,103164420,4171,Unspecified,,,,,Permeability in human skin after 48 hrs by Franz cell permeability assay,Other,19963379.0,
154,455986,3,5,,103164420,4171,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
155,467611,3,6,,103164420,4171,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
156,467612,3,6,,103164420,4171,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
157,467613,5,3,,103164420,4171,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
158,476929,3,3,,103164420,4171,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
159,481439,3,4,,103164420,4171,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
160,481440,3,4,,103164420,4171,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,20373811.0,
161,481441,3,6,,103164420,4171,Unspecified,,,,,Aqueous diffusivity at 37C,Other,20373811.0,
162,481442,3,6,,103164420,4171,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
163,481444,3,4,,103164420,4171,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20373811.0,
164,481446,5,1,,103164420,4171,Unspecified,,,,,Effective permeability across human jejunum,Other,20373811.0,
165,526527,3,1,,103164420,4171,Unspecified,,,,,Apparent permeability across human Caco-2 cells,Other,20850971.0,
166,540209,4,3,,103164420,4171,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
167,540210,4,3,,103164420,4171,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
168,540211,2,5,,103164420,4171,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
169,540212,4,3,,103164420,4171,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
170,540213,4,3,,103164420,4171,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
171,540214,4,3,,103164420,4171,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
172,540215,3,2,,103164420,4171,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
173,540216,4,3,,103164420,4171,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
174,540217,4,3,,103164420,4171,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
175,540218,4,3,,103164420,4171,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
176,540219,4,3,,103164420,4171,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
177,540220,4,3,,103164420,4171,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
178,540221,4,3,,103164420,4171,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
179,540230,2,5,,103164420,4171,Unspecified,,,,,Dose normalised AUC in rat after po administration,Other,16019946.0,
180,540231,2,5,,103164420,4171,Unspecified,,,,,Dose normalised AUC in dog after po administration,Other,16019946.0,
181,540232,2,5,,103164420,4171,Unspecified,,,,,Dose normalised AUC in monkey after po administration,Other,16019946.0,
182,540233,2,5,,103164420,4171,Unspecified,,,,,Dose normalised AUC in human after po administration,Other,16019946.0,
183,540276,1,2,,50103878,4171,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
184,540276,1,2,,50103879,4171,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
185,540276,1,2,,50103880,4171,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
186,568158,1,4,,103164420,4171,Unspecified,,,,,Apparent permeability across human Caco2 cells,Other,21256006.0,
187,588211,2,3,,103164420,4171,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
188,588212,2,3,,103164420,4171,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
189,588213,2,3,,103164420,4171,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
190,588214,2,3,,103164420,4171,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
191,588215,2,3,,103164420,4171,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
192,588216,2,3,,103164420,4171,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
193,588217,2,3,,103164420,4171,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
194,588218,2,3,,103164420,4171,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
195,588219,2,3,,103164420,4171,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
196,588220,2,3,,103164420,4171,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
197,592681,1,4,,103164420,4171,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
198,592684,1,3,,103164420,4171,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,21401113.0,
199,602332,1,1,,50103878,4171,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
200,603955,1,3,,103164420,4171,Unspecified,,,,,"In-vivo blood to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
201,604020,1,4,,103164420,4171,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
202,604021,3,1,,103164420,4171,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
203,604022,1,4,,103164420,4171,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
204,604023,1,3,,103164420,4171,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
205,604024,1,3,,103164420,4171,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
206,604025,1,4,,103164420,4171,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
207,604026,1,4,,103164420,4171,Unspecified,,,,,Unbound CSF to plasma concentration ratio in human,Other,19764786.0,
208,608394,1,4,,103164420,4171,Unspecified,,,,,Permeability of the compound at 100 uM after 5 hrs by PAMPA,Other,21700466.0,
209,624030,1,2,,50103878,4171,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
210,624101,1,2,,85789202,4171,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
211,624137,1,1,,85789202,4171,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
212,624156,1,1,,85789202,4171,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
213,624170,1,1,,50103878,4171,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
214,624172,1,1,,50103878,4171,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
215,624173,1,3,,50103878,4171,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
216,624260,1,1,,85789202,4171,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
217,624349,1,2,,92309031,4171,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
218,625144,5,5,,103164420,4171,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
219,625145,4,7,,103164420,4171,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
220,625146,5,5,,103164420,4171,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
221,625147,4,7,,103164420,4171,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
222,625148,4,7,,103164420,4171,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
223,625149,4,7,,103164420,4171,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
224,625150,5,5,,103164420,4171,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
225,625151,4,7,,103164420,4171,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
226,625152,4,7,,103164420,4171,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
227,625153,4,7,,103164420,4171,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
228,625154,4,7,,103164420,4171,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
229,625155,4,7,,103164420,4171,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
230,625156,1,9,,103164420,4171,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
231,625157,6,2,,103164420,4171,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
232,625158,3,4,,103164420,4171,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
233,625159,5,5,,103164420,4171,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
234,625160,1,9,,103164420,4171,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
235,625161,4,7,,103164420,4171,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
236,625162,4,7,,103164420,4171,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
237,625163,4,7,,103164420,4171,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
238,625164,1,6,,103164420,4171,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
239,625165,3,4,,103164420,4171,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
240,625166,3,4,,103164420,4171,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
241,625167,5,5,,103164420,4171,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
242,625168,4,7,,103164420,4171,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
243,625169,1,6,,103164420,4171,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
244,625170,3,4,,103164420,4171,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
245,625171,4,7,,103164420,4171,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
246,625172,4,7,,103164420,4171,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
247,625173,5,5,,103164420,4171,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
248,625174,5,5,,103164420,4171,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
249,625175,5,5,,103164420,4171,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
250,625176,1,9,,103164420,4171,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
251,625177,5,5,,103164420,4171,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
252,625178,5,5,,103164420,4171,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
253,625179,1,9,,103164420,4171,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
254,625180,5,5,,103164420,4171,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
255,625181,5,5,,103164420,4171,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
256,625182,5,5,,103164420,4171,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
257,625183,5,5,,103164420,4171,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
258,625184,5,5,,103164420,4171,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
259,625185,5,5,,103164420,4171,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
260,625186,5,5,,103164420,4171,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
261,625187,5,5,,103164420,4171,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
262,625188,1,9,,103164420,4171,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
263,625189,1,7,,103164420,4171,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
264,625190,4,5,,103164420,4171,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
265,625191,4,7,,103164420,4171,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
266,625192,4,7,,103164420,4171,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
267,625193,5,5,,103164420,4171,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
268,625194,4,7,,103164420,4171,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
269,625195,4,7,,103164420,4171,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
270,625196,5,6,,103164420,4171,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
271,625197,3,4,,103164420,4171,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
272,625198,4,7,,103164420,4171,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
273,625199,4,7,,103164420,4171,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
274,625200,4,7,,103164420,4171,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
275,625201,4,7,,103164420,4171,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
276,625202,4,7,,103164420,4171,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
277,625203,4,7,,103164420,4171,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
278,625204,4,7,,103164420,4171,Active,48429211.0,153.0,0.17600000000000002,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
279,625205,4,7,,103164420,4171,Active,296439450.0,154.0,2.573,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
280,625206,4,7,,103164420,4171,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
281,625207,4,7,,103164420,4171,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
282,625208,5,5,,103164420,4171,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
283,625209,4,7,,103164420,4171,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
284,625210,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
285,625211,1,6,,103164420,4171,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
286,625212,3,4,,103164420,4171,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
287,625213,4,7,,103164420,4171,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
288,625214,1,9,,103164420,4171,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
289,625215,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
290,625216,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
291,625217,4,7,,103164420,4171,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
292,625218,4,7,,103164420,4171,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
293,625219,3,4,,103164420,4171,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
294,625220,4,7,,103164420,4171,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
295,625221,4,7,,103164420,4171,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
296,625222,4,7,,103164420,4171,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
297,625223,4,7,,103164420,4171,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
298,625224,3,4,,103164420,4171,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
299,625225,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
300,625226,4,7,,103164420,4171,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
301,625227,4,7,,103164420,4171,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
302,625228,4,7,,103164420,4171,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
303,625229,5,5,,103164420,4171,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
304,625230,1,6,,103164420,4171,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
305,625231,4,7,,103164420,4171,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
306,625232,1,9,,103164420,4171,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
307,625233,4,7,,103164420,4171,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
308,625234,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
309,625235,4,7,,103164420,4171,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
310,625236,5,5,,103164420,4171,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
311,625237,4,7,,103164420,4171,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
312,625238,4,7,,103164420,4171,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
313,625239,4,7,,103164420,4171,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
314,625240,1,9,,103164420,4171,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
315,625241,4,7,,103164420,4171,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
316,625242,4,7,,103164420,4171,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
317,625243,5,5,,103164420,4171,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
318,625244,5,5,,103164420,4171,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
319,625245,5,5,,103164420,4171,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
320,625246,1,9,,103164420,4171,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
321,625247,5,5,,103164420,4171,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
322,625248,5,5,,103164420,4171,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
323,625249,5,5,,103164420,4171,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
324,625250,5,5,,103164420,4171,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
325,625251,5,5,,103164420,4171,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
326,625252,4,7,,103164420,4171,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
327,625253,4,7,,103164420,4171,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
328,625254,4,7,,103164420,4171,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
329,625255,4,7,,103164420,4171,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
330,625256,4,7,,103164420,4171,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
331,625257,4,7,,103164420,4171,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
332,625258,4,7,,103164420,4171,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
333,625259,4,7,,103164420,4171,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
334,625260,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
335,625261,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
336,625262,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
337,625263,4,7,,103164420,4171,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
338,625264,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
339,625265,1,6,,103164420,4171,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
340,625266,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
341,625267,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
342,625268,4,2,,103164420,4171,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
343,625268,4,2,,103164420,4171,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
344,625268,4,2,,103164420,4171,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
345,625268,4,2,,103164420,4171,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
346,625269,4,7,,103164420,4171,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
347,625270,4,7,,103164420,4171,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
348,625271,5,5,,103164420,4171,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
349,625272,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
350,625273,4,6,,103164420,4171,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
351,625274,1,6,,103164420,4171,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
352,625275,3,4,,103164420,4171,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
353,625277,1,3,,103164420,4171,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
354,625279,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
355,625280,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
356,625281,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
357,625282,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
358,625283,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
359,625284,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
360,625285,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
361,625286,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
362,625287,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
363,625288,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
364,625289,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
365,625290,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
366,625291,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
367,625292,1,3,,103164420,4171,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
368,627924,1,4,,103164420,4171,Unspecified,,,,,Apparent permeability across apical to basolateral side of dog MDCK cells at 50 uM measured every 15 mins for 1.5 hrs by LC-MS/MS analysis,Other,21669526.0,
369,651828,1,2,,92309031,4171,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
370,678834,1,8,,103164420,4171,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco-2 cells,Other,12948010.0,
371,679583,1,8,,103164420,4171,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 uM, Metprolol: 50 uM) in MDR1-expressing LLC-PK1 cells",Other,11895100.0,
372,681382,1,8,,103164420,4171,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Verapamil binding in membranes from Vinblastine-induced Caco-2 cells,Other,9862789.0,
373,681963,1,7,,103164420,4171,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of cimetidine uptake (Cimetidine: 100 uM, Metoprolol: 1000 uM) in OCT2-expressing mIMCD3 cells",Other,10960071.0,
374,686977,2,1,,49698871,4171,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
375,699539,1,7,,103164420,4171,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
376,699540,1,7,,103164420,4171,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
377,699541,1,7,,103164420,4171,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
378,714178,1,2,,103164420,4171,Unspecified,,,,,Apparent permeability across human Caco2 cells at 10 uM,Other,22305612.0,
379,720641,1,2,,92309031,4171,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
380,720717,1,3,,92309031,4171,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
381,726910,1,2,,103164420,4171,Unspecified,,,,,Apparent permeability across apical to basolateral side in human Caco2/TC7 cells after 2 hrs,Other,23228469.0,
382,730251,3,1,,103164420,4171,Unspecified,,,,,Permeability across human Caco2 cells,Other,23360431.0,
383,777140,1,1,,103164420,4171,Unspecified,,,1000.0,IC50,Inhibition of RyR2 R4496C mutant (unknown origin)-mediated store-overload induced calcium release expressed in HEK293 cells after 8 to 10 mins by fura-2/AM dye-based fluorescence assay,Confirmatory,24124794.0,
384,781326,1,2,,103164420,4171,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
385,781328,1,2,,103164420,4171,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
386,932417,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070710,Other,,
387,932418,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070710,Other,,
388,932419,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070710,Other,,
389,932420,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070710,Other,,
390,932421,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070710,Other,,
391,932422,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070710,Other,,
392,932423,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070710,Other,,
393,932424,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070710,Other,,
394,932425,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070710,Other,,
395,932426,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070710,Other,,
396,932427,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070710,Other,,
397,932428,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070710,Other,,
398,932429,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070710,Other,,
399,932430,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070710,Other,,
400,932431,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070710,Other,,
401,932432,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070710,Other,,
402,932433,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070710,Other,,
403,935837,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070710,Other,,
404,935838,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070710,Other,,
405,935839,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070710,Other,,
406,935840,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070710,Other,,
407,935841,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070710,Other,,
408,935842,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070710,Other,,
409,935843,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070710,Other,,
410,935844,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070710,Other,,
411,935845,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070710,Other,,
412,935846,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070710,Other,,
413,935847,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070710,Other,,
414,935848,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070710,Other,,
415,935849,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070710,Other,,
416,935850,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070710,Other,,
417,935851,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070710,Other,,
418,935852,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070710,Other,,
419,935853,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070710,Other,,
420,938428,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S021021,Other,,
421,938429,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S021021,Other,,
422,938430,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S021021,Other,,
423,938431,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S021021,Other,,
424,938432,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S021021,Other,,
425,938433,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S021021,Other,,
426,938434,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S021021,Other,,
427,938435,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S021021,Other,,
428,938436,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S021021,Other,,
429,938437,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S021021,Other,,
430,938438,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S021021,Other,,
431,940458,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S021021,Other,,
432,940459,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S021021,Other,,
433,940460,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S021021,Other,,
434,940461,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S021021",Other,,
435,940462,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S021021,Other,,
436,940463,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S021021,Other,,
437,940464,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S021021,Other,,
438,940465,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S021021,Other,,
439,940466,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070710,Other,,
440,940467,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070710,Other,,
441,940468,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070710,Other,,
442,940469,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070710,Other,,
443,940470,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070710,Other,,
444,940471,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070710,Other,,
445,940472,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070710,Other,,
446,940473,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070710,Other,,
447,940474,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070710,Other,,
448,940475,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070710,Other,,
449,940476,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070710,Other,,
450,940477,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070710,Other,,
451,940478,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070710,Other,,
452,940479,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070710,Other,,
453,940480,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070710,Other,,
454,940481,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070710,Other,,
455,940482,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070710,Other,,
456,942149,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S021021,Other,,
457,942150,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S021021,Other,,
458,942151,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S021021,Other,,
459,942152,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S021021,Other,,
460,942153,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S021021",Other,,
461,942154,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S021021,Other,,
462,942155,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S021021,Other,,
463,942156,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S021021,Other,,
464,942157,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S021021,Other,,
465,942158,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S021021,Other,,
466,942159,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S021021,Other,,
467,944809,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S021021,Other,,
468,944810,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S021021,Other,,
469,944811,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S021021,Other,,
470,944812,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S021021,Other,,
471,944813,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S021021,Other,,
472,944814,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S021021,Other,,
473,944815,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S021021,Other,,
474,944816,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S021021,Other,,
475,953075,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S021021,Other,,
476,953076,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S021021,Other,,
477,953077,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S021021,Other,,
478,953078,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S021021,Other,,
479,953079,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S021021,Other,,
480,953080,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S021021,Other,,
481,953081,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S021021,Other,,
482,953082,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S021021,Other,,
483,953083,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S021021,Other,,
484,953084,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S021021,Other,,
485,953085,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S021021,Other,,
486,953086,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S021021,Other,,
487,953087,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S021021,Other,,
488,953088,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S021021,Other,,
489,953089,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S021021,Other,,
490,953090,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S021021,Other,,
491,953091,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S021021,Other,,
492,953092,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S021021,Other,,
493,953093,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S021021,Other,,
494,960597,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070710,Other,,
495,960598,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070710,Other,,
496,960599,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070710,Other,,
497,960600,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070710,Other,,
498,960601,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070710,Other,,
499,960602,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070710,Other,,
500,960603,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070710,Other,,
501,960604,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070710,Other,,
502,960605,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070710,Other,,
503,960606,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070710,Other,,
504,960607,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070710,Other,,
505,961040,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070710,Other,,
506,961041,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070710,Other,,
507,961042,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R070710,Other,,
508,961043,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070710,Other,,
509,961044,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070710,Other,,
510,961045,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070710,Other,,
511,961046,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070710,Other,,
512,961047,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070710,Other,,
513,963731,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070710,Other,,
514,964732,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070710,Other,,
515,964733,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070710,Other,,
516,964734,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070710,Other,,
517,964735,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070710,Other,,
518,965114,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070710,Other,,
519,965115,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070710,Other,,
520,965116,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070710,Other,,
521,965117,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070710,Other,,
522,965118,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070710,Other,,
523,965119,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070710,Other,,
524,965120,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070710,Other,,
525,965121,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R070710,Other,,
526,965122,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070710,Other,,
527,965123,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070710,Other,,
528,965124,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070710,Other,,
529,965125,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070710,Other,,
530,965126,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070710,Other,,
531,965127,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070710,Other,,
532,967002,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S021021,Other,,
533,967003,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S021021,Other,,
534,967004,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S021021,Other,,
535,967005,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S021021,Other,,
536,967006,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S021021,Other,,
537,967007,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S021021,Other,,
538,967008,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S021021,Other,,
539,967009,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S021021,Other,,
540,967010,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S021021,Other,,
541,967011,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S021021,Other,,
542,967642,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S021021,Other,,
543,967643,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S021021,Other,,
544,967644,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S021021,Other,,
545,967645,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S021021,Other,,
546,967646,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S021021,Other,,
547,969671,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S021021,Other,,
548,969672,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S021021,Other,,
549,969673,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S021021,Other,,
550,969674,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S021021,Other,,
551,969675,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070710,Other,,
552,969676,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070710,Other,,
553,969677,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070710,Other,,
554,969678,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070710,Other,,
555,969679,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070710,Other,,
556,969680,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070710,Other,,
557,969681,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070710,Other,,
558,969682,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070710,Other,,
559,969683,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070710,Other,,
560,969684,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070710,Other,,
561,969685,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070710,Other,,
562,969686,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070710,Other,,
563,969687,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070710,Other,,
564,969688,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070710,Other,,
565,969689,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070710,Other,,
566,969690,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070710,Other,,
567,969691,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070710,Other,,
568,969692,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R070710,Other,,
569,969693,1,3,,103164420,4171,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070710,Other,,
570,1016493,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S021021",Other,,
571,1016494,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021021",Other,,
572,1016495,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S021021",Other,,
573,1016496,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S021021",Other,,
574,1016497,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021021",Other,,
575,1016498,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S021021",Other,,
576,1016499,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S021021",Other,,
577,1016500,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021021",Other,,
578,1016501,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S021021",Other,,
579,1016502,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S021021",Other,,
580,1016503,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S021021",Other,,
581,1016504,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S021021",Other,,
582,1016505,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S021021",Other,,
583,1016506,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S021021",Other,,
584,1016507,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021021",Other,,
585,1016508,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S021021",Other,,
586,1016509,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021021",Other,,
587,1016510,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S021021",Other,,
588,1016511,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S021021",Other,,
589,1016512,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021021",Other,,
590,1016513,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S021021",Other,,
591,1016514,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021021",Other,,
592,1016515,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021021",Other,,
593,1016516,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021021",Other,,
594,1016517,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S021021",Other,,
595,1016518,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S021021",Other,,
596,1016519,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S021021",Other,,
597,1016520,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S021021",Other,,
598,1016521,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S021021",Other,,
599,1016522,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S021021",Other,,
600,1016523,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S021021",Other,,
601,1016524,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070710",Other,,
602,1017106,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
603,1017107,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
604,1017108,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070710",Other,,
605,1017109,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070710",Other,,
606,1017110,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070710",Other,,
607,1017111,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070710",Other,,
608,1018984,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070710",Other,,
609,1018985,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070710",Other,,
610,1018986,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
611,1018987,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
612,1018988,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070710",Other,,
613,1018989,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070710",Other,,
614,1018990,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
615,1018991,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070710",Other,,
616,1018992,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070710",Other,,
617,1018993,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070710",Other,,
618,1018994,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070710",Other,,
619,1018995,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070710",Other,,
620,1018996,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070710",Other,,
621,1018997,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
622,1025733,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070710",Other,,
623,1025734,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
624,1025735,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
625,1025736,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070710",Other,,
626,1025737,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070710",Other,,
627,1025738,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070710",Other,,
628,1025739,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070710",Other,,
629,1025740,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070710",Other,,
630,1025741,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070710",Other,,
631,1025742,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
632,1025743,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
633,1025744,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070710",Other,,
634,1025745,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070710",Other,,
635,1025746,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
636,1025747,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070710",Other,,
637,1025748,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070710",Other,,
638,1025749,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070710",Other,,
639,1025750,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070710",Other,,
640,1025751,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070710",Other,,
641,1025752,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070710",Other,,
642,1025753,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
643,1033502,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070710",Other,,
644,1033503,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
645,1033504,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
646,1033505,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070710",Other,,
647,1033506,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070710",Other,,
648,1033507,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070710",Other,,
649,1033508,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070710",Other,,
650,1033509,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070710",Other,,
651,1033510,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070710",Other,,
652,1033511,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
653,1033512,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
654,1033513,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070710",Other,,
655,1033514,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070710",Other,,
656,1033515,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
657,1033516,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070710",Other,,
658,1033517,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070710",Other,,
659,1033518,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070710",Other,,
660,1035385,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070710",Other,,
661,1035386,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070710",Other,,
662,1035387,1,4,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070710",Other,,
663,1035388,1,3,,103164420,4171,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
664,1064760,1,1,,103164420,4171,Unspecified,,,,,Apparent permeability in human Caco2 cells,Other,24417583.0,
665,1079931,1,1,,103164420,4171,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
666,1079932,1,1,,103164420,4171,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
667,1079933,1,1,,103164420,4171,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
668,1079934,1,1,,103164420,4171,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
669,1079935,1,1,,103164420,4171,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
670,1079936,1,1,,103164420,4171,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
671,1079937,1,1,,103164420,4171,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
672,1079938,1,1,,103164420,4171,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
673,1079939,1,1,,103164420,4171,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
674,1079940,1,1,,103164420,4171,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
675,1079941,1,1,,103164420,4171,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
676,1079942,1,1,,103164420,4171,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
677,1079943,1,1,,103164420,4171,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
678,1079944,1,1,,103164420,4171,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
679,1079945,1,1,,103164420,4171,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
680,1079946,1,1,,103164420,4171,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
681,1079947,1,1,,103164420,4171,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
682,1079948,1,1,,103164420,4171,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
683,1079949,1,1,,103164420,4171,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
684,1091955,1,2,,103164420,4171,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
685,1091956,1,1,,103164420,4171,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
686,1091957,1,1,,103164420,4171,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
687,1091958,2,1,,103164420,4171,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
688,1096321,1,2,,103164420,4171,Unspecified,,,,,Inhibition of Capra hircus (goat) brain DPP-3 using Arg-Arg-4mbetaNA as substrate assessed as liberation of 4mbetaNA from substrate at 0.5 mM,Other,,
689,1096323,1,2,,103164420,4171,Unspecified,,,230.0,Ki,Competitive inhibition of Capra hircus (goat) brain DPP-3 using Arg-Arg-4mbetaNA as substrate assessed as liberation of 4mbetaNA from substrate preincubated for 10 min by Cornish-Bowden plot analysis,Confirmatory,,
690,1096324,1,2,,103164420,4171,Unspecified,,,315.0,IC50,Inhibition of Capra hircus (goat) brain DPP-3 using Arg-Arg-4mbetaNA as substrate assessed as liberation of 4mbetaNA from substrate,Confirmatory,,
691,1096325,1,2,,103164420,4171,Active,,,,,Inhibition of Capra hircus (goat) brain DPP-3 using Arg-Arg-4mbetaNA as substrate assessed as liberation of 4mbetaNA from substrate at 1 mM,Other,,
692,1129361,1,1,,103164420,4171,Unspecified,,,,,Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis,Other,24601604.0,
693,1159520,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
694,1159521,1,1,,251919670,4171,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
695,1159523,1,1,,251919670,4171,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
696,1159525,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
697,1159526,1,1,,251919670,4171,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
698,1159527,1,1,,251919670,4171,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
699,1159528,1,1,,251919670,4171,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
700,1159529,1,1,,251919670,4171,Inconclusive,,,0.5494,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
701,1159531,1,1,,251919670,4171,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
702,1159551,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
703,1159552,1,1,,251919670,4171,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
704,1159555,1,1,,251919670,4171,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
705,1159580,2,1,,268734624,4171,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
706,1159607,2,1,,312596400,4171,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
707,1159620,1,1,,103164420,4171,Active,,,,,Summary of drug indications.,Other,,
708,1181747,1,1,,103164420,4171,Unspecified,,,,,Effective permeability from apical to basolateral side in human Caco2 cells at 50 uM after 15 to 90 mins by HPLC analysis,Other,24980118.0,
709,1181757,1,2,,103164420,4171,Unspecified,,,,,Effective permeability in Wistar rat small intestine at 50 uM measured after 5 mins in every 5 min interval up to 30 mins,Other,24980118.0,
710,1181758,1,2,,103164420,4171,Unspecified,,,,,Effective permeability in Wistar rat small intestine assessed as absorption rate coefficient at 50 uM measured after 5 mins in every 5 min interval up to 30 mins,Other,24980118.0,
711,1209581,1,2,,103164420,4171,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
712,1209582,1,1,,103164420,4171,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
713,1209583,1,1,,103164420,4171,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
714,1209593,1,1,,103164420,4171,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
715,1210069,1,2,,103164420,4171,Active,21264413.0,1573.0,4.87,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
716,1210070,1,2,,103164420,4171,Unspecified,84028191.0,1565.0,50.0,IC50,Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method,Confirmatory,23033255.0,
717,1210071,1,2,,103164420,4171,Unspecified,116241312.0,1576.0,50.0,IC50,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,Confirmatory,23033255.0,
718,1210072,1,2,,103164420,4171,Unspecified,6686268.0,1559.0,50.0,IC50,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,Confirmatory,23033255.0,
719,1210073,1,2,,103164420,4171,Unspecified,60416369.0,1557.0,50.0,IC50,Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method,Confirmatory,23033255.0,
720,1210074,1,2,,103164420,4171,Unspecified,117144.0,1544.0,50.0,IC50,Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method,Confirmatory,23033255.0,
721,1211789,1,2,,103164420,4171,Unspecified,,,,,Permeability of the compound in human jejunum,Other,23264448.0,
722,1211790,1,2,,103164420,4171,Unspecified,,,,,Permeability in mouse jejunum,Other,23264448.0,
723,1211791,1,1,,103164420,4171,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
724,1211792,1,1,,103164420,4171,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
725,1211793,1,1,,103164420,4171,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,21998403.0,
726,1211794,1,2,,103164420,4171,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
727,1211795,1,1,,103164420,4171,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21998403.0,
728,1211796,1,1,,103164420,4171,Unspecified,,,,,Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
729,1211797,1,1,,103164420,4171,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
730,1211798,1,1,,103164420,4171,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
731,1220973,1,2,,103164420,4171,Unspecified,,,,,Drug distribution in healthy Wistar rat perfused liver assessed as equilibrium amount ratio charactering slow binding process at 3 mM after 10 mins,Other,21245286.0,
732,1220977,1,2,,103164420,4171,Unspecified,,,,,Drug distribution in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed as equilibrium amount ratio charactering slow binding process at 3 mM after 10 mins,Other,21245286.0,
733,1220979,1,1,,103164420,4171,Unspecified,,,,,"Octanol-water apparent partition coefficient, log Papp of the compound at pH 7.4",Other,21245286.0,
734,1220980,1,1,,103164420,4171,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21245286.0,
735,1220983,1,1,,103164420,4171,Unspecified,,,,,Extraction ratio of the compound in healthy Wistar rat perfused liver at 3 mM after 10 mins,Other,21245286.0,
736,1220987,1,1,,103164420,4171,Unspecified,,,,,Extraction ratio of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 3 mM after 10 mins,Other,21245286.0,
737,1220991,1,1,,103164420,4171,Unspecified,,,,,Mean transit time of the compound in healthy Wistar rat perfused liver at 3 mM after 10 mins,Other,21245286.0,
738,1220995,1,1,,103164420,4171,Unspecified,,,,,Mean transit time of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 3 mM after 10 mins,Other,21245286.0,
739,1220999,1,1,,103164420,4171,Unspecified,,,,,Permeability surface area product in healthy Wistar rat perfused liver assessed per gm of liver at 3 mM after 10 mins,Other,21245286.0,
740,1221003,1,1,,103164420,4171,Unspecified,,,,,Permeability surface area product in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed per gm of liver at 3 mM after 10 mins,Other,21245286.0,
741,1221007,1,2,,103164420,4171,Unspecified,,,,,Apparent distribution ratio of the compound in healthy Wistar rat perfused liver at 3 mM after 10 mins,Other,21245286.0,
742,1221011,1,2,,103164420,4171,Unspecified,,,,,Apparent distribution ratio of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 3 mM after 10 mins,Other,21245286.0,
743,1221015,1,1,,103164420,4171,Unspecified,,,,,Intrinsic elimination clearance in healthy Wistar rat perfused liver assessed per gm of liver at 3 mM after 10 mins,Other,21245286.0,
744,1221019,1,1,,103164420,4171,Unspecified,,,,,Intrinsic elimination clearance in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed per gm of liver at 3 mM after 10 mins,Other,21245286.0,
745,1222793,1,1,,103164420,4171,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
746,1223488,1,1,,103164420,4171,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4",Other,22096083.0,
747,1223489,1,1,,103164420,4171,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake flask method",Other,22096083.0,
748,1223490,1,1,,103164420,4171,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells,Other,22096083.0,
749,1223491,1,1,,103164420,4171,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells at 500 uM after 1 hr by HPLC-DAD analysis,Other,22096083.0,
750,1224834,3,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
751,1224835,1,1,,251919670,4171,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
752,1224836,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
753,1224837,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
754,1224838,1,1,,251919670,4171,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
755,1224839,1,1,,251919670,4171,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
756,1224840,3,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
757,1224841,3,1,,251919670,4171,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
758,1224842,3,1,,251919670,4171,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
759,1224843,1,1,,251919670,4171,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
760,1224844,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
761,1224845,1,1,,251919670,4171,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
762,1224846,1,1,,251919670,4171,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
763,1224847,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
764,1224848,3,1,,251919670,4171,Inconclusive,325495545.0,2101.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
765,1224849,3,1,,251919670,4171,Inactive,325495545.0,2101.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
766,1224863,1,1,,176484408,4171,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
767,1224863,1,1,,316920394,4171,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
768,1224867,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
769,1224868,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
770,1224869,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
771,1224870,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
772,1224871,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
773,1224872,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
774,1224873,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
775,1224874,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
776,1224875,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
777,1224876,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
778,1224877,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
779,1224878,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
780,1224879,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
781,1224880,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
782,1224881,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
783,1224882,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
784,1224883,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
785,1224884,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
786,1224885,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
787,1224886,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
788,1224887,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
789,1224888,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
790,1224889,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
791,1224890,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
792,1224892,1,1,,251919670,4171,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
793,1224893,1,1,,251919670,4171,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
794,1224894,1,1,,251919670,4171,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
795,1224895,1,1,,251919670,4171,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
796,1224896,1,1,,251919670,4171,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
797,1224905,2,1,,92309031,4171,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
798,1224905,2,1,,92309031,4171,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
799,1232308,1,1,,103164420,4171,Unspecified,,,,,"Distribution coefficient, log D of the compound",Other,25799158.0,
800,1232310,1,1,,103164420,4171,Unspecified,,,,,Volume of distribution at steady state in human,Other,25799158.0,
801,1232311,1,1,,103164420,4171,Unspecified,,,,,Unbound volume of distribution at steady state in human,Other,25799158.0,
802,1232312,1,1,,103164420,4171,Unspecified,,,,,Clearance in human,Other,25799158.0,
803,1232313,1,1,,103164420,4171,Unspecified,,,,,Elimination half life in human,Other,25799158.0,
804,1232314,1,1,,103164420,4171,Unspecified,,,,,Unbound intrinsic clearance in human,Other,25799158.0,
805,1232324,1,1,,103164420,4171,Active,48429211.0,153.0,0.01585,Kd,Antagonist activity against beta-1 adrenergic receptor (unknown origin),Confirmatory,25799158.0,
806,1259241,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
807,1259242,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
808,1259243,1,1,,251919670,4171,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
809,1259244,1,1,,251919670,4171,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
810,1259247,1,1,,251919670,4171,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
811,1259248,1,1,,251919670,4171,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
812,1259310,1,1,,321942044,4171,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
813,1259364,1,1,,251919670,4171,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
814,1259365,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
815,1259366,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
816,1259367,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
817,1259368,1,1,,251919670,4171,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
818,1259369,1,1,,251919670,4171,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
819,1259377,1,1,,251919670,4171,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
820,1259378,1,1,,251919670,4171,Inconclusive,54288833.0,2100.0,43.2771,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
821,1259379,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
822,1259380,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
823,1259381,1,1,,251919670,4171,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
824,1259382,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
825,1259383,1,1,,251919670,4171,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
826,1259384,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
827,1259385,1,1,,251919670,4171,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
828,1259386,1,1,,251919670,4171,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
829,1259387,1,1,,251919670,4171,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
830,1259388,1,1,,251919670,4171,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
831,1259390,1,1,,251919670,4171,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
832,1259391,1,1,,251919670,4171,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
833,1259392,1,1,,251919670,4171,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
834,1259393,1,1,,251919670,4171,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
835,1259394,1,1,,251919670,4171,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
836,1259395,1,1,,251919670,4171,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
837,1259396,1,1,,251919670,4171,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
838,1259401,1,1,,251919670,4171,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
839,1259402,1,1,,251919670,4171,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
840,1259403,1,1,,251919670,4171,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
841,1259404,1,1,,251919670,4171,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
842,1259416,1,2,,340080241,4171,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
843,1259416,1,2,,375178263,4171,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
844,1259421,1,1,,340080241,4171,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
845,1259421,1,1,,375178263,4171,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
846,1259423,1,2,,354765104,4171,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
847,1259423,1,2,,354828295,4171,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
848,1259423,1,2,,354919935,4171,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
849,1259423,1,2,,354971361,4171,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
